The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy
Study Details
Study Description
Brief Summary
This is a double blinded two-arm randomized case-only interventional trial. A total of 60 patients who are to receive Paclitaxel to be included and allocated in two groups. The protocol is to be reviewed by the Research Ethics Committee of Faculty of Medicine Cairo University.
All procedure will be done in Kasr El-Einy Center of Radiation Oncology and Nuclear Medicine.
The first arm (Venlafaxine group) will receive Venlafaxine extended release (37.5 mg) tablets (Zimmerman et al., 2016).
The second arm (Memantine group) will receive memantine 10 mg once daily (Morel et al., 2016)
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2/Phase 3 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Venlafaxine Treated Arm
|
Drug: Venlafaxine
Patients will receive will receive Venlafaxine extended release (37.5 mg) tablets once daily(Zimmerman et al., 2016)
|
| Experimental: Memantine Treated Arm
|
Drug: Memantine
Patients will receive memantine (10 mg) once daily (Morel et al., 2016)
|
Outcome Measures
Primary Outcome Measures
- Change in average daily pain intensity [6 weeks]
Change in average daily pain intensity as measured by the Brief Pain Inventory- Short Form (BPI-SF). Absolute change in the average daily pain intensity as measured by the Brief Pain Inventory- Short Form (BPI-SF) from baseline to the end of 6 weeks measured by item # 5 of Brief Pain Inventory Score (BPI-SF). The BPI assesses pain at its "worst," "least," "average," and "now" (current pain).
- Electrophysiological studies [6 weeks]
nerve conduction velocity at the end of the study
Eligibility Criteria
Criteria
Inclusion Criteria:
-
All patients, 18 years of age or older, with a cancer treated with Paclitaxel
-
Patients must have a life expectancy of at least 24 weeks.
-
Patients must sign an informed consent.
-
Patients may have a grade 0 (chemotherapy naive) or 1 neuropathy (history of prior chemotherapy) prior to entry.
-
Patient matching high risk on the CIPN risk stratification scoring system
Exclusion Criteria:
-
Patients with symptomatic brain metastases.
-
Pregnant women or nursing mothers. Patients of child bearing potential must use adequate contraception.
-
Patients may receive no other concurrent complementary medicines during this study.
-
Patients with neuropathy induced diabetes.
-
Patients with severe medical problems such as uncontrolled diabetes mellitus or cardiovascular disease or active infections.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Faculty of Medicine Cairo University - Kasr El-Einy Center of Radiation Oncology and Nuclear Medicine | Cairo | Egypt | 11562 |
Sponsors and Collaborators
- Mendel AI
- Cairo University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CIPN101